Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Toshihiro Sato, Shinjiro Kodama, Keizo Kaneko, Junta Imai, Hideki Katagiri
Abstract
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Topics & Concepts
NivolumabMedicineDiabetes mellitusVaccinationType 2 Diabetes MellitusImmune systemIncidence (geometry)Adverse effectImmunologyCoronavirus disease 2019 (COVID-19)Type 1 diabetesInternal medicineImmunotherapyDiseaseEndocrinologyInfectious disease (medical specialty)PhysicsOpticsCancer Immunotherapy and BiomarkersDiabetes and associated disordersCOVID-19 Clinical Research Studies